818 Stock Overview
A medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zylox-Tonbridge Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.53 |
| 52 Week High | HK$1.57 |
| 52 Week Low | HK$1.50 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -2.55% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 818 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -1.3% |
| 1Y | n/a | -8.4% | 7.4% |
Return vs Industry: Insufficient data to determine how 818 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 818 performed against the German Market.
Price Volatility
| 818 volatility | |
|---|---|
| 818 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 818 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 818's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 594 | Jonathon Zhao | www.zyloxtb.com |
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, stenosis, carotid artery, and vascular access device. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products.
Zylox-Tonbridge Medical Technology Co., Ltd. Fundamentals Summary
| 818 fundamental statistics | |
|---|---|
| Market cap | €449.48m |
| Earnings (TTM) | -€21.10m |
| Revenue (TTM) | €35.18m |
12.8x
P/S Ratio-21.3x
P/E RatioIs 818 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 818 income statement (TTM) | |
|---|---|
| Revenue | CN¥259.17m |
| Cost of Revenue | CN¥63.94m |
| Gross Profit | CN¥195.23m |
| Other Expenses | CN¥350.71m |
| Earnings | -CN¥155.48m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Mar 29, 2023
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 75.33% |
| Net Profit Margin | -59.99% |
| Debt/Equity Ratio | 0% |
How did 818 perform over the long term?
See historical performance and comparison